In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration
Graphical abstract
Introduction
Pneumonia (whether either community- or hospital-acquired) is a leading cause of morbidity, quality-adjusted life year loss, and mortality in children, adults, and the elderly. Furthermore, an alarming rise in levels of antimicrobial resistance is compromising the effective prevention and treatment of pneumonia. The opportunistic pneumonia-causing pathogens Pseudomonas aeruginosa (P. aeruginosa) is often associated with devastating, acute disease, and chronic infections [1,2]. Pseudomonas aeruginosa is one of the most prevalent infectious agents in intensive care units, and is the leading cause of ventilator-associated pneumonia in patients being treated for trauma or severe viral infections. Moreover, P. aeruginosa-associated lung infections are associated with significantly higher mortality than infections with other pathogens [3,4]. The prevention and treatment of P. aeruginosa infections are challenging, in view of the bacterium's genetic and biochemical versatility and intrinsic resistance to antibiotics [5]. Overall, the data show that the significant increase in antibiotic resistance over the last 15 years has been associated with greater premature mortality [6].
The low number of novel antibiotics coming onto the market means that novel alternative or complementary anti-infectious strategies are urgently needed. One such strategy involves the use of therapeutic antibodies (Abs), which have already proven successful in the prevention or treatment of infectious lung diseases. Three anti-infectious Abs have been approved for clinical use: the humanized IgG1 palivizumab for the prevention of respiratory syncytial virus infection in high-risk infants, and the human IgG1 raxibacumab and the chimeric IgG1 obiltoxaximab for the prophylaxis and/or treatment of pulmonary anthrax. Furthermore, 12 Abs targeting respiratory pathogens (including 4 Abs against P. aeruginosa) are in clinical development [7].
In the clinic, most therapeutic antibodies (and, indeed, most therapeutic proteins) are administered parenterally, i.e. via the intravenous (i.v.), subcutaneous (s.c.) or intramuscular (i.m.) route. Oral administration is not indicated because therapeutic proteins are not usually formulated to resist acid denaturation in the stomach or proteolytic degradation in the rest of the gastrointestinal tract. Most Abs for the treatment of respiratory tract infections are administered i.v. [7]. However, this route is unlikely to be optimal for therapeutic designed to treat respiratory diseases; the few available literature data indicate that only a small fraction of the injected Ab reaches the lungs/airways [[8], [9], [10]]. Given that large amounts of Ab are usually required to protect against infections, an Ab's systemic distribution after i.v. injection might limit efficacy while increasing the risk of systemic toxicity (serum thickening, cytokine release syndrome).
As the body's main entry portal for innocuous or harmful environmental antigens, the airways represent an attractive delivery route for drugs designed to treat respiratory diseases. We and others have recently demonstrated that the airway route is feasible for the delivery of Ab-based therapeutics [[11], [12], [13], [14], [15], [16], [17], [18]]. The Abs induce a treatment response, and pass slowly into the systemic circulation [[19], [20], [21], [22]]. Furthermore, it has been shown that Ab-based therapeutics are sensitive to aerosolization but can retain their physical and immunological properties when delivered with specific devices and after the addition of specific excipients [16].
Overall, the results of preclinical studies have shown that inhaled Abs are therapeutically active and thus underpin the growing interest in the pulmonary/airway route [7,23,24]. Nevertheless, the literature data on the advantages and disadvantages of parenteral versus local routes of anti-infective Ab administration are scarce. It is probably highly important to take account of situations in which the alveolus-capillary barrier is altered, since this might change the fate of and response to Abs. In the present study (performed in a murine model of acute pneumonia), we investigated the pharmacokinetics (PK) and protective activity of an archetypal anti-P. aeruginosa Ab as a function of its administration route. We found that airway administration of Ab was associated with a favorable PK profile, longer retention in the lung compartment, and a stronger anti-bacterial response by the host (characterized by enhanced neutrophil recruitment and bacterial clearance, and attenuated lung permeability). Local administration of Ab was also associated with a less intense acute inflammatory response, lower levels of pro-inflammatory cytokines.
Section snippets
Mice and reagents
Adult male C57BL/6jrj (B6) mice (6 to 8 weeks old) were obtained from Janvier (France). All mice were housed under specific-pathogen-free conditions at the PST Animaleries animal facility (France) and had access to food and water ad libitum. All animal experiments complied with the current European legislative, regulatory and ethical requirements and were approved by the local animal care and use committee (reference: APAFIS#7608-2016111515206630).
mAb166 was generated using a PTA-9180 hybridoma
Acute lung infection by P. aeruginosa PA103 is associated with impairment of the alveolus-capillary barrier
We compared the standard parenteral routes used to administer Abs in the clinic (i.v. and s.c.) with local airway administration. Given that the i.p. route is often used to deliver drugs in preclinical studies, we also included it in our experiments.
To assess the PK, PD and safety profiles of the anti-P. aeruginosa Ab as a function of its administration route, we first established and characterized an acute pneumonia model (using the clinical isolate P. aeruginosa PA103) derived from that
Discussion
Although many different P. aeruginosa antigens have been investigated as parenterally administered immunotherapeutics or vaccine candidates (e.g. lipopolysaccharide, flagellin, and pilins), their efficacy remains limited [33,34]. This may be because the parenteral administration route is not optimal. Since the main pathophysiological mechanisms underlying P. aeruginosa infection act within the lungs, matching the Ab's delivery route to the pathogenic target's location may produce a higher
Competing interests statement
The authors have no competing interests to declare.
Acknowledgements
This work was supported by a public grant overseen by the French National Research Agency (ANR) as part of the “Investissements d'Avenir” program (LabEx MAbImprove, ANR-10-LABX-53-01). TS is funded by a fellowship from ANR-10-LABX-53-01.
We sincerely thank David Fraser PhD (Biotech Communication SARL, France) for copy-editing services.
References (48)
- et al.
Therapeutic antibodies: a new era in the treatment of respiratory diseases?
Pharmacol. Ther.
(September 2018) - et al.
Properties of human IgG1s engineered for enhanced binding to the neonatal fc receptor (FcRn)
J. Biol. Chem.
(2006) - et al.
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
J. Allergy Clin. Immunol.
(2001) - et al.
PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract
J. Control. Rel.
(2014) - et al.
Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin
J. Control. Rel.
(2016) - et al.
Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system
J. Control. Rel.
(2014) - et al.
The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation
J. Mol. Biol.
(2013) - et al.
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
J. Immunol. Methods
(2005) - et al.
Innate immune responses to Pseudomonas aeruginosa infection
Microbes Infect.
(2011) - et al.
Vaccines and immunotherapy against Pseudomonas aeruginosa
Vaccine
(2008)
KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
J. Cystic Fibrosis
Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease
Clinical Infect. Dis.
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations
Thorax
Ventilator-associated pneumonia
Am. J. Respir. Crit. Care Med.
Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States
J. Chemother.
Update on the treatment of Pseudomonas aeruginosa pneumonia
J. Antimicrob. Chemother.
Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa
Clinical Infect. Dis.
Pharmacokinetics of intravenous immunoglobulin: a systematic review
Pharmacotherapy
The safety and side effects of monoclonal antibodies
Nat. Rev. Drug Discov.
Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma
Am. J. Respir. Cell Mol. Biol.
Administration of antibody to the lung protects mice against pneumonic plague
Infect. Immun.
Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization
Pharm. Res.
Effect of formulation on the stability and aerosol performance of a nebulized antibody
mAbs
Nebulization as a delivery method for mAbs in respiratory diseases
Expert Opin. Drug Deliv.
Cited by (17)
Influence of mesh nebulizer characteristics on aerosol delivery in non-human primates
2023, European Journal of Pharmaceutical SciencesThe role of airway mucus and diseased pulmonary epithelium on the absorption of inhaled antibodies
2023, International Journal of PharmaceuticsA Systematic Safety Evaluation of Nanoporous Mannitol Material as a Dry-Powder Inhalation Carrier System
2020, Journal of Pharmaceutical SciencesCitation Excerpt :Pulmonary drug delivery systems have been one of the most effective approaches for respiratory diseases1-3 because of the advantages of high local drug concentration, no first-pass effect in the lungs.4,5
Evaluation of antibody drug delivery efficiency via nebulizer in various airway models and breathing patterns
2023, BMC Pharmacology and Toxicology
- 1
Contributed equally to this work.